<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity dstore:dataset="ifcwbg-tr" dstore:index="91" hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-44558</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">GHP RSE Nobel</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">Access to Pharmaceuticals: IFC will support Nobel to continue supplying high quality medication to around 50 countries. Nobel&apos;s sales are largely in Europe and Central Asia with a focus on countries such as Turkey, Bulgaria, Ukraine, Kazakhstan, Uzbekistan, and Kosovo. 
Job Preservation: IFC will support job preservation during this unprecedent time at Nobel, which has more than 1,500 employees in Turkey.
Resilience: IFC will promote resilience of the Turkish pharmaceuticals market through supporting a leading local drug maker during a pandemic. With Covid-19, the market is under significant strain as service providers face depleted supplies. IFC&apos;s support to Nobel will contribute towards strengthening the local supply chain.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">The proposed IFC investment consists of a senior loan to Nobel Ilac Sanayii ve Ticaret A.S. (Nobel or the Company) in form of an A Loan up to EUR10 million or its USD or TRY equivalent. The IFC loan fits into IFCs crisis response for Covid-19 financing and will reduce Nobels working capital pressure triggered by the effects of Covid-19. That way, Nobel will uninterruptedly carry out its ongoing capex program in the areas of injectables and bio-technology.  Nobel is a Turkish generic pharmaceuticals company that produces, markets, distributes and sells products domestically and exports across Europe and Central Asia. Its product portfolio is spread across chronic, acute and consumer health therapeutic areas.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">NOBEL ILAC SANAYII VE TICARET A.S.</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-44558" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2021-03-23" type="1"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">0  0  0  0  0  0  0  0  0.0000         Nobel   Ilac     Sanayii   ve   Ticaret   A.S.    Saray     Doktor   Adnan   Buyukdeniz     Caddesi     Akcakoca   Sokak     Umraniye   / Istanbul   Turkiye</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Nobel Ilac Sanayii ve Ticaret A.S.  Mrs. Esra Eke  Chief Financial Officer  +90 (216) 633 60 00  Esra.eke@nobel.com.tr  Saray Doktor Adnan Buyukdeniz Caddesi Akcakoca Sk. 34768 Umraniye Istanbul Turkiye  www.nobel.com.tr</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="TR" percentage="100">
   <narrative xml:lang="EN">Turkey</narrative>
  </recipient-country>
  <location ref="TR-Turkey">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">The project location is in Turkey. Nobel is headquartered in Istanbul while its other premises are located in Duzce and Gebze.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>39.0000000000 35.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">other</narrative>
  </sector>
  <tag code="COVID-19" vocabulary="99"></tag>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $11.73 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/44558">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/44558">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
